RTS,S

RTS,S or Mosquirix is en experimental vaccine for malaria developed by GlaxoSmithKline.[1]

In October 2011, preliminary findings from a Phase III trial of RTS,S reported that it may protect approximately 50% of inoculated infants and children (decline in final mortality rate unverified). The RTS,S vaccine was engineered using genes from the outer protein of Plasmodium falciparum malaria parasite and a portion of a hepatitis B virus and a chemical adjuvant to boost the immune system response.[2] The RTS,S-based vaccine formulation had previously been demonstrated to be safe, well tolerated, immunogenic, and to potentially confer partial efficacy in both malaria-naive and -experienced adults as well as children, although further research was considered necessary to improve the effectiveness of the vaccine.[3] It is being developed by PATH and GlaxoSmithKline (GSK) and Bill and Melinda Gates Foundation[4]

References

  1. ^ "Malaria scientist celebrates success after 24 years".
  2. ^ Agnandji ST, Lell B, Soulanoudjingar SS, et al. (November 2011). "First Results of Phase 3 Trial of RTS,S/AS01 Malaria Vaccine in African Children". New England Journal of Medicine 365 (20): 1863-1875. doi:10.1056/NEJMoa1102287. PMID 22007715.  edit
  3. ^ Regules JA, Cummings JF, Ockenhouse CF (May 2011). "The RTS,S vaccine candidate for malaria". Expert Rev Vaccines 10 (5): 589–99. doi:10.1586/erv.11.57. PMID 21604980. 
  4. ^ Stein, R. Experimental malaria vaccine protects many children, study shows. Washington Post 18 October 2011.